D
Avricore Health Inc.
AVCR.V
TSX
D
Sell
12/2/2024Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D from D- on 12/2/2024 due to a large increase in the efficiency index, volatility index and solvency index. Total capital increased 10.72% from $1.66M to $1.84M.
Avricore Health Inc. (AVCR.V) was upgraded to D from D- on 12/2/2024 due to a large increase in the efficiency index, volatility index and solvency index. Total capital increased 10.72% from $1.66M to $1.84M.
D
Sell
11/15/2024Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to D- from D on 11/15/2024 due to a substantial decline in the total return index, volatility index and growth index.
Avricore Health Inc. (AVCR.V) was downgraded to D- from D on 11/15/2024 due to a substantial decline in the total return index, volatility index and growth index.
D
Sell
9/6/2024Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D from D- on 9/6/2024 due to a significant increase in the valuation index, total return index and solvency index. The quick ratio increased from 1.71 to 2.62.
Avricore Health Inc. (AVCR.V) was upgraded to D from D- on 9/6/2024 due to a significant increase in the valuation index, total return index and solvency index. The quick ratio increased from 1.71 to 2.62.
D
Sell
7/24/2024Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 7/24/2024 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from $0.0004 to $0.0013, EBIT increased 134.16% from $56.5 to $132.3, and operating cash flow increased 65.22% from $182.3 to $301.2.
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 7/24/2024 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from $0.0004 to $0.0013, EBIT increased 134.16% from $56.5 to $132.3, and operating cash flow increased 65.22% from $182.3 to $301.2.
E
Sell
5/9/2024Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 5/9/2024 due to a decline in the valuation index and volatility index.
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 5/9/2024 due to a decline in the valuation index and volatility index.
D
Sell
4/29/2024Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 4/29/2024 due to an increase in the solvency index, total return index and volatility index.
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 4/29/2024 due to an increase in the solvency index, total return index and volatility index.
E
Sell
4/3/2024Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 4/3/2024 due to a decline in the total return index, solvency index and volatility index.
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 4/3/2024 due to a decline in the total return index, solvency index and volatility index.
D
Sell
3/18/2024Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 3/18/2024 due to an increase in the volatility index and valuation index.
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 3/18/2024 due to an increase in the volatility index and valuation index.
E
Sell
3/1/2024Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 3/1/2024 due to a decline in the total return index and volatility index.
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 3/1/2024 due to a decline in the total return index and volatility index.
D
Sell
2/15/2024Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 2/15/2024 due to an increase in the volatility index and valuation index.
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 2/15/2024 due to an increase in the volatility index and valuation index.
E
Sell
1/30/2024Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 1/30/2024 due to a decline in the total return index and volatility index.
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 1/30/2024 due to a decline in the total return index and volatility index.
D
Sell
12/8/2023Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 12/8/2023 due to an increase in the valuation index.
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 12/8/2023 due to an increase in the valuation index.
E
Sell
8/1/2023Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 8/1/2023 due to a major decline in the total return index, volatility index and growth index. Total revenue declined 35.39% from $720 to $465.2.
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 8/1/2023 due to a major decline in the total return index, volatility index and growth index. Total revenue declined 35.39% from $720 to $465.2.
D
Sell
3/29/2023Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index.
Avricore Health Inc. (AVCR.V) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index.
E
Sell
3/14/2023Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D on 3/14/2023 due to a significant decline in the total return index.
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D on 3/14/2023 due to a significant decline in the total return index.
D
Sell
2/9/2023Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Avricore Health Inc. (AVCR.V) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 13.02 to 3.31.
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 13.02 to 3.31.
D
Sell
5/16/2022Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D from E+ on 05/16/2022.
Avricore Health Inc. (AVCR.V) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
4/22/2022Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D from D- on 4/22/2022 due to a large increase in the growth index. Earnings per share increased from -$0.0036 to -$0.0017, EBIT increased 35.16% from -$348.7 to -$226.1, and operating cash flow increased 15.53% from -$257.5 to -$217.5.
Avricore Health Inc. (AVCR.V) was upgraded to D from D- on 4/22/2022 due to a large increase in the growth index. Earnings per share increased from -$0.0036 to -$0.0017, EBIT increased 35.16% from -$348.7 to -$226.1, and operating cash flow increased 15.53% from -$257.5 to -$217.5.
D
Sell
4/20/2022Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the growth index, total return index and solvency index. EBIT declined 24.23% from -$280.7 to -$348.7, earnings per share declined from -$0.003 to -$0.0036, and the quick ratio declined from 12.57 to 11.76.
Avricore Health Inc. (AVCR.V) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the growth index, total return index and solvency index. EBIT declined 24.23% from -$280.7 to -$348.7, earnings per share declined from -$0.003 to -$0.0036, and the quick ratio declined from 12.57 to 11.76.
D
Sell
11/9/2021Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D from E+ on 11/09/2021.
Avricore Health Inc. (AVCR.V) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D on 11/8/2021 due to a noticeable decline in the growth index and valuation index. Total revenue declined 33.33% from $6 to $4, and operating cash flow declined 21.62% from -$230.3 to -$280.1.
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D on 11/8/2021 due to a noticeable decline in the growth index and valuation index. Total revenue declined 33.33% from $6 to $4, and operating cash flow declined 21.62% from -$230.3 to -$280.1.
D
Sell
5/18/2020Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D from D- on 5/18/2020 due to a noticeable increase in the growth index and volatility index.
Avricore Health Inc. (AVCR.V) was upgraded to D from D- on 5/18/2020 due to a noticeable increase in the growth index and volatility index.
D
Sell
5/1/2020Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, solvency index and volatility index. Total capital declined 141.64% from -$141.7 to -$342.4, and the quick ratio declined from 0.19 to 0.04.
Avricore Health Inc. (AVCR.V) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, solvency index and volatility index. Total capital declined 141.64% from -$141.7 to -$342.4, and the quick ratio declined from 0.19 to 0.04.
D
Sell
11/29/2019Upgraded
Avricore Health Inc. (AVCR.V) was upgraded to D from E+ on 11/29/2019 due to a significant increase in the efficiency index and valuation index.
Avricore Health Inc. (AVCR.V) was upgraded to D from E+ on 11/29/2019 due to a significant increase in the efficiency index and valuation index.
E
Sell
5/31/2019Downgrade
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 5/31/2019 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 2.56 to 0.77.
Avricore Health Inc. (AVCR.V) was downgraded to E+ from D- on 5/31/2019 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 2.56 to 0.77.
D
Sell
1/4/2018Upgraded
Vanc Pharmaceuticals Inc. (VANC.V) was upgraded to D- from E+ on 1/4/2018 due to an increase in the volatility index and total return index.
Vanc Pharmaceuticals Inc. (VANC.V) was upgraded to D- from E+ on 1/4/2018 due to an increase in the volatility index and total return index.
E
Sell
11/30/2017Downgrade
Vanc Pharmaceuticals Inc. (VANC.V) was downgraded to E+ from D- on 11/30/2017 due to a significant decline in the growth index, total return index and solvency index. EBIT declined 51.72% from -$319.8 to -$485.2, operating cash flow declined 35.41% from -$426.7 to -$577.8, and total revenue declined 25.95% from $134.1 to $99.3.
Vanc Pharmaceuticals Inc. (VANC.V) was downgraded to E+ from D- on 11/30/2017 due to a significant decline in the growth index, total return index and solvency index. EBIT declined 51.72% from -$319.8 to -$485.2, operating cash flow declined 35.41% from -$426.7 to -$577.8, and total revenue declined 25.95% from $134.1 to $99.3.
D
Sell
12/6/2016Upgraded
Vanc Pharmaceuticals Inc. (VANC.V) was upgraded to D- from E+ on 12/6/2016 due to an increase in the valuation index.
Vanc Pharmaceuticals Inc. (VANC.V) was upgraded to D- from E+ on 12/6/2016 due to an increase in the valuation index.
E
Sell
11/21/2016Downgrade
Vanc Pharmaceuticals Inc. (NPH.V) was downgraded to E+ from D- on 11/21/2016 due to a significant decline in the total return index, volatility index and valuation index.
Vanc Pharmaceuticals Inc. (NPH.V) was downgraded to E+ from D- on 11/21/2016 due to a significant decline in the total return index, volatility index and valuation index.
D
Sell
3/11/2016Downgrade
Vanc Pharmaceuticals Inc. (NPH.V) was downgraded to D- from D on 3/11/2016 due to a noticeable decline in the volatility index and valuation index.
Vanc Pharmaceuticals Inc. (NPH.V) was downgraded to D- from D on 3/11/2016 due to a noticeable decline in the volatility index and valuation index.
D
Sell
11/11/2014Upgraded
Vanc Pharmaceuticals Inc. (NPH.V) was upgraded to D from D- on 11/11/2014 due to a noticeable increase in the growth index, efficiency index and volatility index. EBIT increased 5.12% from -$193.3 to -$203.2, and net income increased 2.07% from -$212.6 to -$217.
Vanc Pharmaceuticals Inc. (NPH.V) was upgraded to D from D- on 11/11/2014 due to a noticeable increase in the growth index, efficiency index and volatility index. EBIT increased 5.12% from -$193.3 to -$203.2, and net income increased 2.07% from -$212.6 to -$217.
D
Sell
10/30/2014Downgrade
Vanc Pharmaceuticals Inc. (NPH.V) was downgraded to D- from D on 10/30/2014 due to a noticeable decline in the total return index, valuation index and volatility index.
Vanc Pharmaceuticals Inc. (NPH.V) was downgraded to D- from D on 10/30/2014 due to a noticeable decline in the total return index, valuation index and volatility index.
D
Sell
8/19/2014Upgraded
Vanc Pharmaceuticals Inc. (NPH.V) was upgraded to D from D- on 8/19/2014 due to an increase in the valuation index.
Vanc Pharmaceuticals Inc. (NPH.V) was upgraded to D from D- on 8/19/2014 due to an increase in the valuation index.
D
Sell
8/4/2014Downgrade
Nuva Pharmaceuticals Inc. (NPH.V) was downgraded to D- from D on 8/4/2014 due to a noticeable decline in the volatility index, growth index and efficiency index. Earnings per share declined from -$0.0095 to -$0.0091.
Nuva Pharmaceuticals Inc. (NPH.V) was downgraded to D- from D on 8/4/2014 due to a noticeable decline in the volatility index, growth index and efficiency index. Earnings per share declined from -$0.0095 to -$0.0091.
D
Sell
3/13/2014Upgraded
Nuva Pharmaceuticals Inc. (NPH.V) was upgraded to D from D- on 3/13/2014 due to a noticeable increase in the volatility index, total return index and growth index.
Nuva Pharmaceuticals Inc. (NPH.V) was upgraded to D from D- on 3/13/2014 due to a noticeable increase in the volatility index, total return index and growth index.
